|
1
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mevissen TET and Komander D: Mechanisms of
deubiquitinase specificity and regulation. Annu Rev Biochem.
86:159–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lai KP, Chen J and Tse WKF: Role of
deubiquitinases in human cancers: Potential targeted therapy. Int J
Mol Sci. 21:25482020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li S, Zhang H and Wei X: Roles and
Mechanisms of Deubiquitinases (DUBs) in breast cancer progression
and targeted drug discovery. Life (Basel). 11:9652021.PubMed/NCBI
|
|
9
|
Pareja F, Ferraro DA, Rubin C,
Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon
R, Crosetto N, et al: Deubiquitination of EGFR by Cezanne-1
contributes to cancer progression. Oncogene. 31:4599–4608. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang JH, Wei W, Guo ZX, Shi M and Guo RP:
Decreased Cezanne expression is associated with the progression and
poor prognosis in hepatocellular carcinoma. J Transl Med.
13:412015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang B, Wang H, Yang L, Zhang Y, Wang P,
Huang G, Zheng J, Ren H and Qin S: OTUD7B and NIK expression in
non-small cell lung cancer: Association with clinicopathological
features and prognostic implications. Pathol Res Pract.
212:893–898. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang JH, Zhong XP, Zhang YF, Wu XL, Li SH,
Jian PE, Ling YH, Shi M, Chen MS, Wei W, et al: Cezanne predicts
progression and adjuvant TACE response in hepatocellular carcinoma.
Cell Death Dis. 8:e30432017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lei S, He Z, Chen T, Guo X, Zeng Z, Shen Y
and Jiang J: Long noncoding RNA 00976 promotes pancreatic cancer
progression through OTUD7B by sponging miR-137 involving EGFR/MAPK
pathway. J Exp Clin Cancer Res. 38:4702019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu S, Liu Y, Gui A, Xia Z, Liu W, Gu JJ,
Zuo J, Yang L and Zhang Q: Deubiquitinase OTUD7B is a potential
prognostic biomarker in diffuse large B-cell lymphoma. J Cancer.
13:998–1004. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang J, Wu Z, Tian Z, Chen W and Wu G:
OTUD7B stabilizes estrogen receptor α and promotes breast cancer
cell proliferation. Cell Death Dis. 12:5342021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong Z, Li A, Ding J, Li Q, Zhang L, Li Y,
Meng Z, Chen F, Huang J, Zhou D, et al: OTUD7B Deubiquitinates LSD1
to Govern Its Binding Partner Specificity, Homeostasis, and Breast
Cancer Metastasis. Adv Sci (Weinh). 8:e20045042021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu HW, Lin HY, Tseng IJ and Lin YF:
OTUD7B upregulation predicts a poor response to paclitaxel in
patients with triple-negative breast cancer. Oncotarget. 9:553–565.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Yu Y, Yang M, Huang H, Ma S, Hu J,
Xi Z, Guo H, Yao G, Yang L, et al: YTHDF1 promotes breast cancer
progression by facilitating FOXM1 translation in an m6A-dependent
manner. Cell Biosci. 12:192022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui CP, Zhang Y, Wang C, Yuan F, Li H, Yao
Y, Chen Y, Li C, Wei W, Liu CH, et al: Dynamic ubiquitylation of
Sox2 regulates proteostasis and governs neural progenitor cell
differentiation. Nat Commun. 9:46482018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sher G, Masoodi T, Patil K, Akhtar S,
Kuttikrishnan S, Ahmad A and Uddin S: Dysregulated FOXM1 signaling
in the regulation of cancer stem cells. Semin Cancer Biol.
86:107–121. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bonacci T, Suzuki A, Grant GD, Stanley N,
Cook JG, Brown NG and Emanuele MJ: Cezanne/OTUD7B is a cell
cycle-regulated deubiquitinase that antagonizes the degradation of
APC/C substrates. EMBO J. 37:e987012018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Evans PC, Taylor ER, Coadwell J, Heyninck
K, Beyaert R and Kilshaw PJ: Isolation and characterization of two
novel A20-like proteins. Biochem J. 357:617–623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Evans PC, Smith TS, Lai MJ, Williams MG,
Burke DF, Heyninck K, Kreike MM, Beyaert R, Blundell TL and Kilshaw
PJ: A novel type of deubiquitinating enzyme. J Biol Chem.
278:23180–23186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Enesa K, Zakkar M, Chaudhury H, Luong le
A, Rawlinson L, Mason JC, Haskard DO, Dean JL and Evans PC:
NF-kappaB suppression by the deubiquitinating enzyme Cezanne: A
novel negative feedback loop in pro-inflammatory signaling. J Biol
Chem. 283:7036–7045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu QZ, Liu HY, Zhao XY, Qiu LJ, Zhou TT,
Wang XY, Chen HP and Xiao ZQ: DJ-1 activates the noncanonical NF-κB
pathway via interaction with Cezanne to inhibit the apoptosis and
promote the proliferation of Ishikawa cells. Mol Biol Rep.
48:6075–6083. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin DD, Shen Y, Qiao S, Liu WW, Zheng L,
Wang YN, Cui N, Wang YF, Zhao S and Shi JH: Upregulation of OTUD7B
(Cezanne) promotes tumor progression via AKT/VEGF pathway in lung
squamous carcinoma and adenocarcinoma. Front Oncol. 9:8622019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prasad S, Ramachandran S, Gupta N, Kaushik
I and Srivastava SK: Cancer cells stemness: A doorstep to targeted
therapy. Biochim Biophys Acta Mol Basis Dis. 1866:1654242020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ibragimova M, Tsyganov M and Litviakov N:
Tumour stem cells in breast cancer. Int J Mol Sci. 23:50582022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun HL, Men JR, Liu HY, Liu MY and Zhang
HS: FOXM1 facilitates breast cancer cell stemness and migration in
YAP1-dependent manner. Arch Biochem Biophys. 685:1083492020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Modi A, Purohit P, Roy D, Vishnoi JR,
Pareek P, Elhence P, Singh P, Sharma S, Sharma P and Misra S: FOXM1
mediates GDF-15 dependent stemness and intrinsic drug resistance in
breast cancer. Mol Biol Rep. 49:2877–2888. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsao AN, Chuang YS, Lin YC, Su Y and Chao
TC: Dinaciclib inhibits the stemness of two subtypes of human
breast cancer cells by targeting the FoxM1 and Hedgehog signaling
pathway. Oncol Rep. 47:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y,
Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, et al: ZRANB1 Is
an EZH2 deubiquitinase and a potential therapeutic target in breast
cancer. Cell Rep. 23:823–837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao H, Claret FX and Shen Q: The novel
Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces
apoptosis in human breast cancer cells. Neoplasma. 66:481–486.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song Z, Tu X, Zhou Q, Huang J, Chen Y, Liu
J, Lee S, Kim W, Nowsheen S, Luo K, et al: A novel UCHL3 inhibitor,
perifosine, enhances PARP inhibitor cytotoxicity through inhibition
of homologous recombination-mediated DNA double strand break
repair. Cell Death Dis. 10:3982019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liao Y, Xia X, Liu N, Cai J, Guo Z, Li Y,
Jiang L, Dou QP, Tang D, Huang H, et al: Growth arrest and
apoptosis induction in androgen receptor-positive human breast
cancer cells by inhibition of USP14-mediated androgen receptor
deubiquitination. Oncogene. 37:1896–1910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma A, Tang M, Zhang L, Wang B, Yang Z, Liu
Y, Xu G, Wu L, Jing T, Xu X, et al: USP1 inhibition destabilizes
KPNA2 and suppresses breast cancer metastasis. Oncogene.
38:2405–2419. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He J, Lee HJ, Saha S, Ruan D, Guo H and
Chan CH: Inhibition of USP2 eliminates cancer stem cells and
enhances TNBC responsiveness to chemotherapy. Cell Death Dis.
10:2852019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ahram M, Abdullah MS, Mustafa SA, Alsafadi
DB and Battah AH: Androgen downregulates desmocollin-2 in
association with induction of mesenchymal transition of breast
MDA-MB-453 cancer cells. Cytoskeleton (Hoboken NJ). 78:391–399.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liubomirski Y, Lerrer S, Meshel T,
Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C and Ben-Baruch
A: Tumor-stroma-inflammation networks promote pro-metastatic
chemokines and aggressiveness characteristics in triple-negative
breast cancer. Front Immunol. 10:7572019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pruteanu LL, Braicu C, Módos D, Jurj MA,
Raduly LZ, Zănoagă O, Magdo L, Cojocneanu R, Paşca S, Moldovan C,
et al: Targeting cell death mechanism specifically in triple
negative breast cancer cell lines. Int J Mol Sci. 23:47842022.
View Article : Google Scholar : PubMed/NCBI
|
